Integration of glycemic compensation markers, including glycemic variability in patients with diabetes mellitus
Authors:
Oliver Viktor Rácz 1,2; Eva Lovásová 1; Jaroslava Nováková 1; Adriana Phillipiová 3
Authors‘ workplace:
Ústav patologickej fyziológie LF UPJŠ v Košiciach
1; Fakulta zdravotníckych vied, Univerzita Miškolc/Miskolci Egyetem, Maďarsko
2; Diabetologická ambulancia DIADA s. r. o., Bardejov
3
Published in:
Diab Obez 2024; 24(1): 13-19
Category:
Reviews
Overview
In the first part of the paper an analysis of the factors that are responsible for the variability of glycemia in health and in patients with diabetes mellitus is presented. This is followed by a critical analysis of older and newer indices used to assess glycemic fluctuations in diabetes mellitus and a list of the possible consequences of increased variability on the development of diabetes mellitus comorbidities from a clinical and a pathophysiological point of view. Finally, simplified models of glycemic variability and their perspective for the development of a simple index of short-term glycemic fluctuations as an integrated component of diabetic dysglycemia are presented.
Keywords:
glycemic variability – dysglycemia – glycemic compensation of diabetes mellitus
Sources
Rácz O, Frankel E, Brenišin M. Langerhansove ostrovčeky – metabolický mozog človeka. Interná Med 2022; 22(9): 353–357.
AlSayed NA, Aleppo G, Aroda VR et al. Glycemic 6. Targets: Standards of care in diabetes – 2023. Diabetes Care 2023; 46(Suppl 1): S97-S110. Dostupné z DOI: <http://dx.doi.org/10.2337/dc23-S006>.
[ADA Professional Practice Committee]. Glycaemic goals and hypoglycemia: Standards of Care in Diabetes. Diabetes Care 2024; 47(Suppl 1): S111-S125. Dostupné z DOI: <http://dx.doi.org/10.2337/dc24-S006>.
Joslin EP. Diabetic manual for the doctor and patient. 6th ed. Lea & Fabiger: Philadelphia 1953.
Clarke SF, Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci 2012; 69(2): 83–93.
Rácz, O, Vícha T, Pačin J. Glykohemoglobín, glykácia bielkovín a diabetes mellitus. Osveta: Martin 1989. ISBN 9788021700727.
Gillery P. HbA 1c and biomarkers of diabetes mellitus in Clinical Chemistry and Laboratory Medicine: ten years after. Clin Chem Lab Med 2022; 61(5): 861–872. Dostupné z DOI: <http://dx.doi.org/10.1515/cclm-2022–08941>.
[DCCT Research Group]. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329(14): 977–986. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199309303291401>.
[UK prospective Diabetes Study Group]. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–853.
Nathan DA. [DCCT/EDIC Research Group]. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care 2014; 37(1): 9–16. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–2112>.
Shlichtkrull J, Munck O, Jersild M. The M-value, an index of blood sugar control in diabetics. Acta Med Scand 1965; 177: 95–102. Dostupné z DOI: <http://dx.doi.org/10.1111/j.0954–6820.1965.tb01810.x>.
Service SJ, Molnar GD, Rosevear JW et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes; 1970:19(9): 644–655. Dostupné z DOI: <http://dx.doi.org/10.2337/diab.19.9.644>.
Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 1972; 8(5): 342–348. <http://dx.doi.org/10.1007/BF01218495>.
Cameron FJ, Donath MS, Baghurst PA. Measuring glycaemic variation. Curr Diabetes Rev 2010; 6(1): 17–26. Dostupné z DOI: <http://dx.doi.org/10.2174/157339910790442592>.
Service FJ. Glucose variability. Diabetes 2013; 62(5): 1398–1404. Dostupné z DOI: <http://dx.doi.org/10.2337/db12–1396>.
Wojciciki JM. “J”-Index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 1995; 27(1): 41–41. Dostupné z DOI: <http://dx.doi.org/10.1055/s-2007–979906>.
Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005; 19(3): 178–181. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2004.10.001>.
Rodbard D. Continuous glucose monitoring: A review of successes, challenges, and opportunities. Diabetes Technol Therap 2016; 18(Suppl 2): S3-S13. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2015.0417>.
Prázný M, Šoupal J. Glykemická variabilita a kontinuální monitorace glykemie. Vnitř Lék 2014; 60(9): 757–763.
McDonnel CM, Donath SM, Vidmar SI et al. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005; 7(2): 253–263. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2005.7.253>.
Kovatchev BP, Straume M, Cox DJ et al. Risk analysis of blood glucose data: a quantitative approach to optimizing the control of insulin dependent diabetes. J Theor Med 1995; 3(1): 1–10. Dostupné z DOI: <http://dx.doi.org/10.1080/10273660008833060>.
Kovatchev BP, Otto E, Cox E et al. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006; 29(11): 2433–2438. Dostupné z DOI: <http://dx.doi.org/10.2337/dc06–1085>.
Hill NR, Hindmarsh PC, Stevens RJ et al. A method for assessing quality of control from glucose profiles. A method for assessing quality of control from glucose profiles. Diabetic Med 2007; 24(7): 753–758. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2007.02119.x>.
Klonoff DC, Wang J, Rodbard D et al. A Glycemia Risk Index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings. J Diabetes Sci Technol 2023; 17(5): 1226–1242. Dostupné z DOI: <http://dx.doi.org/10.1177/19322968221085273>.
[ADA Professional Practice Committee]. 7. Diabetes Technology. Standards of Care in Diabetes – 2024. Diabetes Care 2024; 47(Suppl 1): 126–144. Dostupné z DOI: <http://dx.doi.org/10.2337/dc24-S007>.
Donne T, Nimri RN, Battelino T et al. International consensus on use of Continuous Glucose Monitoring. Diabetes Care 2017; 40(12): 1631–1640. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–1600>.
Dunn TC, Nimri R, Battelino T et al Is It time to move beyond TIR to TITR? Real-world data from over 20,000 users of continuous glucose monitoring in patients with Type 1 and Type 2 diabetes. Diab Technol Ther 2024; 26(3): 203–210. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2023.056>.
Rácz O, Linková M, Heriban V et al. HbA1c as the gold standard in monitoring of glycaemic compensation in patients with diabetes mellitus – how to interpret and use the results in a creative way? International conference on chronic diseases and 6th SAVEZ conference. Košice 24.-25. 10. 2019. Book of abstracts. Dostupné z WWW: <https://www.mc3.sk/international-conference-on-chronic-diseases-6th-savez-conference-kosice/>.
Zhang ZY, Miao LF, Qian LL et al. Molecular mechanisms of glucose fluctuations on diabetic complication. Front Endocrin 2019; 10: 640. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2019.00640>.
Zhang X, Yang X, Sun B et al. Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review. Commun Biol 2021; 4(1): 1366. Dostupné z DOI: <http://dx.doi.org/10.1038/s42003–021–02896–3>.
Lontchi-Yimagou E, Sobngwi E, Matsha TE et al. Diabetes Mellitus and Inflammation. Curr Diab Rep 2013; 13(3): 435–444. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892–013–0375-y>.
Prázný M, Škrha J, Šoupal J et al. Krátkodobá a dlouhodobá glykemická variabilita a její vztah k mikrovaskulárním komplikacím diabetu. Vnitř Lék 2016; 62(11 Suppl 4): 4S85–4S93.
Labels
Diabetology ObesitologyArticle was published in
Diabetes and obesity
2024 Issue 1
Most read in this issue
- Early use of SGLT2-inhibitors i in the treatment of type 2 diabetes mellitus
- Current position of GLP-1 receptor agonists in type 2 diabetes mellitus treatment
- Metformin in the treatment of type 2 diabetes mellitus and its current position
- Coexistence of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of a patient with type 2 diabetes mellitus